Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2015 12:13 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
December 09, 2015 01:07 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
December 02, 2015 01:04 ET | Source: Ablynx

JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION GHENT, Belgium, Dec. 2, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC:...
December 01, 2015 01:05 ET | Source: Ablynx

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED...
November 30, 2015 01:14 ET | Source: Ablynx

ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER

Clinical Immunologist with more than 15 years combined FDA and pharmaceutical industry experience Successfully developed a broad range of drugs in a number of important therapeutic...
November 25, 2015 01:06 ET | Source: Ablynx

ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK

Ablynx to receive a €5 million upfront payment, research funding, potential future milestones and royalties on net sale New pharmaceutical partner for Ablynx bringing disease...
November 18, 2015 01:08 ET | Source: Ablynx

ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015

REGULATED INFORMATION Clinical pipeline further advanced with one Phase III and four Phase II studies currently on-going in-house, and first potential product launch in 2018 Significant...
November 05, 2015 01:05 ET | Source: Ablynx

ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY

Bi-specific Nanobody demonstrates superior efficacy as compared to reference monoclonal antibody drugs Bi-specific Nanobody strongly inhibits proliferation and survival of human endothelial...
October 21, 2015 01:08 ET | Source: Ablynx

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION GHENT, Belgium, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
October 15, 2015 01:09 ET | Source: Ablynx

ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC.

Bi-specific Nanobody construct achieves pre-clinical proof-of-concept in tumour model Ablynx to receive €3.5 million milestone payment GHENT/ZWIJNAARDE, Belgium,...